Il Tribunale fallimentare degli Stati Uniti ha concesso un ordine per l'amministrazione congiunta dei casi di bancarotta del Capitolo 11 di Endo International plc e delle sue affiliate il 17 agosto 2022. Le affiliate comprendono Par Pharmaceutical, Inc., Actient Pharmaceuticals, LLC, 70 Maple Avenue, LLC, Anchen Incorporated, Generics International (US), Inc, DAVA Pharmaceuticals, LLC, Endo Par Innovation Company, LLC, Generics Bidco I, LLC, Innoteq, Inc, JHP Acquisition, LLC, JHP Group Holdings, LLC, Kali Laboratories, LLC, Moores Mill Properties L.L.C., Par Pharmaceutical Companies, Inc, Par Pharmaceutical Holdings, Inc, Par Sterile Products, LLC, Par, LLC, Quartz Specialty Pharmaceuticals, LLC, Quartz Specialty Pharmaceuticals, LLC, Actient Therapeutics LLC, Astora Women's Health Ireland Limited, Astora Women's Health, LLC, Auxilium International Holdings, LLC, Auxilium Pharmaceuticals, LLC, Auxilium US Holdings, LLC, Bermuda Acquisition Management Limited, BioSpecifics Technologies LLC, Branded Operations Holdings, Inc, DAVA International, LLC, Endo Aesthetics LLC, Endo Bermuda Finance Limited, Endo Designated Activity Company, Endo Eurofin Unlimited Company, Endo Finance IV Unlimited Company, Endo Finance LLC, Endo Finance Operations LLC, Endo Finco Inc, Endo Global Aesthetics Limited, Endo Global Biologics Limited, Endo Global Development Limited, Endo Global Finance LLC, Endo Global Ventures, Endo Global Ventures, Endo Innovation Valera, LLC, Endo Ireland Finance II Limited, Endo LLC, Endo Luxembourg Finance Company I S.à r.l., Endo Luxembourg Holding Company S.à r.l., Endo Luxembourg International Financing S.à r.l., Endo Management Limited, Endo Pharmaceuticals Finance LLC, Endo Pharmaceuticals Inc., Endo Pharmaceuticals Solutions Inc., Endo Pharmaceuticals Valera Inc., Endo Procurement Operations Limited, Endo TopFin Limited, Endo U.S. Inc, Endo US Holdings Luxembourg I S.à r.l., Endo Ventures Aesthetics Limited, Endo Ventures Bermuda Limited, Endo Ventures Cyprus Limited, Endo Ventures Limited, Generics International (US) 2, Inc., Generics International Ventures Enterprises LLC, Hawk Acquisition Ireland Limited, Kali Laboratories 2, Inc, Luxembourg Endo Specialty Pharmaceuticals Holding I S.à r.l., Paladin Labs Canadian Holding Inc., Paladin Labs Inc., Par Laboratories Europe, Ltd., Par Pharmaceutical 2, Inc., Slate Pharmaceuticals, LLC e Timm Medical Holdings, LLC. I casi saranno gestiti congiuntamente per scopi amministrativi e procedurali.

Endo International plc è stata designata come debitore principale.